{"url_path":"/sec/mreo/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1719714/0001193125-26-343519-index.html","accession_number":"0001193125-26-343519","cik":"0001719714","ticker":"MREO","issuer_name":"Mereo BioPharma Group plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1719714/0001193125-26-343519-index.html","primary_entity_key":"0001719714","primary_entity_name":"Mereo BioPharma Group plc"},"word_count":84,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit No.\n\nDescription of Exhibit\n\n99.1\n\n[Press Release, dated August 11, 2026](mreo-ex99_1.htm).\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n \n\n# SIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\nMEREO BIOPHARMA GROUP PLC\n\n \n\n \n\n \n\nDate: August 11, 2026\n\nBy:\n\n/s/ Christine Fox\n\n \n\n \n\nName:\n\nChristine Fox\n\n \n\n \n\nTitle:\n\nChief Financial Officer"}